Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Classical hematology 1

Conditions

Leukemia 22Leukemia, Promyelocytic, Acute 21Leukemia, Myeloid, Acute 13Multiple Myeloma 11Myelodysplastic Syndromes 9Leukemia, Myelomonocytic, Chronic 8Neoplasms, Plasma Cell 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Monocytic, Acute 5Anemia, Refractory, with Excess of Blasts 5Neoplasms 4Lymphoma 4Leukemia, Myelomonocytic, Acute 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Erythroblastic, Acute 4Central Nervous System Neoplasms 4Blast Crisis 4Recurrence 3Neuroblastoma 3Neoplasm Metastasis 3Myeloproliferative Disorders 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Leukemia, Myeloid, Chronic-Phase 3

Interventions

Cyclophosphamide 42fludarabine phosphate 33Peripheral Blood Stem Cell Transplantation 31Busulfan 31Tacrolimus 24Antilymphocyte Serum 24Cyclosporine 22Mycophenolic Acid 20Filgrastim 20Radiotherapy 19Methotrexate 19Melphalan 17Whole-Body Irradiation 13Methylprednisolone 12Etoposide 12Cord Blood Stem Cell Transplantation 11Cytarabine 9Sirolimus 7Flow Cytometry 7Azacitidine 7Alemtuzumab 7Specimen Handling 6Psychiatric Rehabilitation 6Cyclosporins 6Biopsy 6sargramostim 5ruxolitinib 5Thiotepa 5fludarabine 4Rituximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Myelodysplastic-Myeloproliferative Diseases × Arsenic Trioxide × Clear all
NCT00274820 2020-07-27

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

Case Comprehensive Cancer Center

Phase 2 Completed
15 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00104806 2018-08-10

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

Wake Forest University Health Sciences

Phase 2 Terminated
5 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT00093366 2011-11-30

Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes

Fred Hutchinson Cancer Center

Phase 1/2 Completed
32 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡